Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Its lead programme, firibastat (QGC001), is in a 250-patient Phase IIb study in hypertensive overweight patients with patient dosing expected to be completed by the end of 2018 and data in Q119. Another Phase IIb in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI) is expected to launch
13 Jul 2018
Quantum Genomics - A little company going after big indications
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Quantum Genomics - A little company going after big indications
Quantum Genomics Societe Anonyme (ALQGC:PAR) | 0 0 0.0%
- Published:
13 Jul 2018 -
Author:
Maxim Jacobs -
Pages:
12
Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Its lead programme, firibastat (QGC001), is in a 250-patient Phase IIb study in hypertensive overweight patients with patient dosing expected to be completed by the end of 2018 and data in Q119. Another Phase IIb in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI) is expected to launch